FDA Final Guidance on Topical Drug Product Characterization for ANDAs

Detected March 18th, 2026

Summary

The FDA has issued final guidance for industry on the physicochemical and structural characterization of topical drug products submitted in Abbreviated New Drug Applications (ANDAs). This guidance assists applicants in identifying generic topical products and supporting bioequivalence demonstrations. It finalizes the draft guidance issued in October 2022.

View original document View source feed page

What changed

The Food and Drug Administration (FDA) has released final guidance titled “Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs.” This document provides recommendations for characterization methods to identify the dosage form of proposed generic topical products and to describe critical properties supporting bioequivalence demonstrations for abbreviated new drug applications (ANDAs). This final guidance supersedes the draft version that was issued on October 21, 2022, and is intended for drug manufacturers seeking to market generic topical medications.

Regulated entities, specifically drug manufacturers applying for ANDAs for topical products, should review this guidance to understand the recommended characterization requirements. While the guidance is non-binding, adherence to its recommendations can facilitate the approval process for generic topical drugs. The FDA also notes that comments on any guidance can be submitted at any time, indicating a continuous feedback mechanism for regulatory clarity. No specific compliance deadline is mentioned, but applicants should incorporate these recommendations into their development and submission strategies.

What to do next

Review final FDA guidance on topical drug product characterization for ANDAs
Incorporate recommended physicochemical and structural characterization methods into ANDA submissions for topical products

Source document (simplified)

Search for FDA
Guidance Documents

Docket Number: FDA-2022-D-1864 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research, Office of Regulatory Policy The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs.” This guidance is intended to assist applicants who submit abbreviated new drug applications (ANDAs) for liquid-based and/or other semisolid products applied to the skin, including integumentary and mucosal (e.g., vaginal) membranes (referred to as “topical products”). This guidance provides recommendations for physicochemical and structural (collectively, “Q3”) characterizations that can be used to identify the dosage form of a proposed generic (test) topical product, and to describe properties of the drug product that may be critical to its performance (to support a demonstration of bioequivalence (BE)). This guidance finalizes the draft guidance of the same title issued on October 21, 2022.